All Releases
 |
MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Medical Affairs
Jul 23, 2008
|
9.5 KB |
|
| |
MOUNTAIN VIEW, Calif., July 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Donald J. Kellerman, Pharm.D. to the position of Senior Vice President, Clinical Development and Medical Affairs.
Dr. Kellerman brings to MAP Pharmaceuticals more than 25 years of cli...
|
|
MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
Jul 16, 2008
|
11.2 KB |
|
| |
MOUNTAIN VIEW, Calif., July 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the positive results from a Phase 2 study evaluating the safety, tolerability and pharmacokinetics of MAP0004 in adult asthmatics were published in the July issue of Current Medical Research and Opinion. MAP...
|
|
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
Jul 14, 2008
|
11.0 KB |
|
| |
MOUNTAIN VIEW, Calif., July 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine.
MAP0004 is orally inhaled and self-administered at home using MAP Pharmaceuticals' proprietary Te...
|
|
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
Jun 28, 2008
|
11.3 KB |
|
| |
MOUNTAIN VIEW, Calif., June 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine (DHE) for the potential treatment of migraine, compared to intravenous (IV) DHE. The study results w...
|
|
MAP Pharmaceuticals Acquires Proprietary Drug Particle Formulation Technology From Eiffel/Telesso Technologies Limited
Jun 24, 2008
|
9.2 KB |
|
| |
MOUNTAIN VIEW, Calif., June 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that Telesso Technologies Limited, formerly Eiffel Technologies Limited ("Eiffel"), has agreed to transfer and assign to MAP Pharmaceuticals previously licensed intellectual property and know-how, as well a...
|
|
MAP Pharmaceuticals to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
Jun 4, 2008
|
7.2 KB |
|
| |
MOUNTAIN VIEW, Calif., June 4, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference on Tuesday, June 10, 2008, at 4:00 pm (PT) in Dana Point, California.
A live webcast of the presentatio...
|
|
MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
May 29, 2008
|
7.6 KB |
|
| |
MOUNTAIN VIEW, Calif., May 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Marco F. Rosa to the newly created position of Vice President of Human Resources.
Mr. Rosa brings over 20 years of human resources experience to the Company. Most recently, Mr. Rosa wo...
|
|
MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
May 16, 2008
|
7.1 KB |
|
| |
MOUNTAIN VIEW, Calif., May 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008, at 9:00 am (ET) in New York City.
A live webcast of the presentation will be av...
|
|
MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results
May 12, 2008
|
11.4 KB |
|
| |
MOUNTAIN VIEW, Calif., May 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the first quarter ended March 31, 2008.
The net loss for the first quarter ended March 31, 2008 was $14.3 million compared with $6.7 million during the same period in 2007. As of Ma...
|
|
MAP Pharmaceuticals Secures $20 Million in Debt Financing
May 7, 2008
|
7.1 KB |
|
| |
MOUNTAIN VIEW, Calif., May 7, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company has secured a $20 million working capital loan. Oxford Finance Corporation, the principal lender, and Silicon Valley Bank, a member company of SVB Financial Group (Nasdaq: SIVB), provided the...
|
|
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Apr 25, 2008
|
7.2 KB |
|
| |
MOUNTAIN VIEW, Calif., April 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the following upcoming investor conferences on April 30th and May 6th, 2008:
Morgan Stanley Global Healthcare Conference, Key Biscayne, FL
Wednesday, April 3...
|
|
MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
Apr 7, 2008
|
11.4 KB |
|
| |
MOUNTAIN VIEW, Calif., April 7, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), today announced positive results from a Phase 2a clinical study evaluating MAP0005 for the potential treatment of asthma and chronic obstructive pulmonary disease (COPD). MAP0005 is a single-particle combination of ...
|
|
MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
Mar 25, 2008
|
7.5 KB |
|
| |
MOUNTAIN VIEW, Calif., March 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of financial executive H. Ward Wolff to its board of directors. Mr. Wolff brings over 25 years of financial experience to the board, where he will also serve on the audit committee.
Mr....
|
|
MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
Mar 24, 2008
|
9.2 KB |
|
| |
MOUNTAIN VIEW, Calif., March 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that in a pharmacokinetic clinical trial Unit Dose Budesonide (UDB) demonstrated lower systemic drug exposure when compared to the currently marketed conventional nebulized budesonide. UDB is MAP Pharmaceu...
|
|
MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
Feb 28, 2008
|
14.7 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2007.
The net loss for the fourth quarter and year ended December 31, 2007 was $14.9 million and $40.1 million, respectively, compared...
|
|
MAP Pharmaceuticals Announces Resignation of Chief Medical Officer
Feb 5, 2008
|
7.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, announced today that Stephen B. Shrewsbury, M.B., Ch.B., Chief Medical Officer, will be leaving the company for personal reasons in early March 2008. Dr. Shrewsbury plans to provide cons...
|
|
MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Jan 30, 2008
|
7.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Wednesday, February 6, 2008, at 1:40 pm (ET) in New York City.
A live webcast of t...
|
|
MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
Jan 16, 2008
|
11.2 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, today announced that it has completed the special protocol assessment (SPA) process with the U.S. Food and Drug Administration (FDA) for the first Phase 3 clinical trial of its MAP0004 p...
|
|
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial of Unit Dose Budesonide in Children with Asthma
Jan 7, 2008
|
10.4 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, today announced it has initiated a Phase 3 clinical trial evaluating Unit Dose Budesonide (UDB), the company's proprietary nebulized version of budesonide, for the potential treatment of...
|
|
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 27, 2007
|
7.2 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following upcoming investor conferences on November 28th and December 12th, 2007 in New York City:
Lazard Capital Markets Fourth Annual Healthcare Conference
...
|
|
|
